The discovery of these genes has been critical to the understanding of inherited cancers as well as developing new treatments.
Drugs that are already used in the treatment of ovarian, breast and prostate cancer, where there is a faulty BRCA gene, are being tested on a rare and deadly form of brain tumour.
Cancer Research UK funded a trial, led by the University of Glasgow, to look at the effectiveness of PARP inhibitors (a type of targeted cancer drug) as part of treatment for glioblastoma.
It is one of the most common types of brain tumours in adults, affecting up to 4,000 people a year in the UK, and has poor survival rates.
Prof Anthony Chalmers, who is leading the second phase of the trial, said a breakthrough would be “massive” as outcomes for patients were bleak.
“Everybody with this cancer essentially dies because of that tumour and the cancers in the brain also cause all kinds of problems with disabilities, memory and personality,” he said.
“Like with the BRCA discovery, we hope it won’t just be brain tumour patients who benefit from this and we can apply what we learn in this particular cancer to other types of cancer.”
For Lisa, the research and potential for further ways to prevent and treat cancers following the discovery of the BRCA genes is what “brings her peace” for her daughter’s future after initially feeling “absolutely devastated”.
In Scotland, people can be referred for genetic testing after they turn 18, if they meet one of the risk criteria.
People may be referred for the test by their GP if cancer runs in their family, if a relative has a faulty gene or if they have a Jewish grandparent.
Recent research found a geographical ancestral link in Orkney and Shetland by scientists in Edinburgh and Aberdeen universities.
